LLY

749.3

-0.7%↓

JNJ

177.72

-0.2%↓

ABBV

216.91

-0.64%↓

UNH

348.68

-1.2%↓

AZN

78.03

-1.9%↓

LLY

749.3

-0.7%↓

JNJ

177.72

-0.2%↓

ABBV

216.91

-0.64%↓

UNH

348.68

-1.2%↓

AZN

78.03

-1.9%↓

LLY

749.3

-0.7%↓

JNJ

177.72

-0.2%↓

ABBV

216.91

-0.64%↓

UNH

348.68

-1.2%↓

AZN

78.03

-1.9%↓

LLY

749.3

-0.7%↓

JNJ

177.72

-0.2%↓

ABBV

216.91

-0.64%↓

UNH

348.68

-1.2%↓

AZN

78.03

-1.9%↓

LLY

749.3

-0.7%↓

JNJ

177.72

-0.2%↓

ABBV

216.91

-0.64%↓

UNH

348.68

-1.2%↓

AZN

78.03

-1.9%↓

Search

Ovid therapeutics Inc

Abrir

SetorSaúde

1.25 0.81

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.2

Máximo

1.27

Indicadores-chave

By Trading Economics

Rendimento

5.6M

-4.7M

Vendas

6.1M

6.3M

Margem de lucro

-74.681

Funcionários

23

EBITDA

7.3M

-5.1M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+169.84% upside

Dividendos

By Dow Jones

Próximos Ganhos

10 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

49M

88M

Abertura anterior

0.44

Fecho anterior

1.25

Sentimento de Notícias

By Acuity

100%

0%

356 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Ovid therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de set. de 2025, 22:41 UTC

Grandes Movimentos do Mercado

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 de set. de 2025, 16:04 UTC

Grandes Movimentos do Mercado

Upexi Shares Climb on Solana Gains

14 de set. de 2025, 23:48 UTC

Conversa de Mercado

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14 de set. de 2025, 23:41 UTC

Conversa de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

14 de set. de 2025, 23:38 UTC

Conversa de Mercado

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14 de set. de 2025, 23:13 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 de set. de 2025, 23:13 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

14 de set. de 2025, 23:13 UTC

Conversa de Mercado

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14 de set. de 2025, 23:13 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

14 de set. de 2025, 23:04 UTC

Conversa de Mercado

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13 de set. de 2025, 08:20 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

12 de set. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

12 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

12 de set. de 2025, 20:09 UTC

Ganhos

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 de set. de 2025, 19:23 UTC

Conversa de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 de set. de 2025, 19:16 UTC

Conversa de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 de set. de 2025, 19:03 UTC

Conversa de Mercado

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 de set. de 2025, 18:59 UTC

Conversa de Mercado

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 de set. de 2025, 18:38 UTC

Conversa de Mercado
Ganhos

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 de set. de 2025, 18:33 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 de set. de 2025, 18:22 UTC

Conversa de Mercado

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 de set. de 2025, 16:56 UTC

Conversa de Mercado

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 de set. de 2025, 16:22 UTC

Ganhos

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 de set. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

12 de set. de 2025, 16:19 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 de set. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

12 de set. de 2025, 16:11 UTC

Ganhos

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 de set. de 2025, 15:37 UTC

Conversa de Mercado

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 de set. de 2025, 15:22 UTC

Conversa de Mercado

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 de set. de 2025, 15:07 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Comparação entre Pares

Variação de preço

Ovid therapeutics Inc Previsão

Preço-alvo

By TipRanks

169.84% parte superior

Previsão para 12 meses

Média 3.4 USD  169.84%

Máximo 5.5 USD

Mínimo 1.5 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

7

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.275 / 0.33Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

356 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat